📣 VC round data is live. Check it out!

Sino Biological Valuation Multiples

Discover Sino Biological's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical and more.

Sino Biological Overview

About Sino Biological

Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.


Founded

2016

HQ

China

Employees

N/A

Financials (FY)

Revenue: $103M
EBITDA: $40M

EV

$671M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Sino Biological Financials

Sino Biological reported last fiscal year revenue of $103M and EBITDA of $40M.

In the same fiscal year, Sino Biological generated $76M in gross profit, $40M in EBITDA, and $22M in net income.

Revenue (LTM)


Sino Biological P&L

In the most recent fiscal year, Sino Biological reported revenue of $103M and EBITDA of $40M.

Sino Biological is profitable as of last fiscal year, with gross margin of 73%, EBITDA margin of 39%, and net margin of 21%.

See analyst estimates for Sino Biological
Last FY202320242025202620272028
Revenue$103M$96M$91M$103M
Gross Profit$76M$78M$66M$76M
Gross Margin73%82%73%73%
EBITDA$40M$53M$35M$40M
EBITDA Margin39%56%39%39%
EBIT Margin15%25%9%15%
Net Profit$22M$38M$18M$22M
Net Margin21%40%20%21%

Financial data powered by Morningstar, Inc.

Sino Biological Stock Performance

Sino Biological has current market cap of $1B, and enterprise value of $671M.

Market Cap Evolution


Sino Biological's stock price is $9.41.

Sino Biological share price increased by 0.9% in the last 30 days, and decreased by 4.8% in the last year.

Sino Biological has an EPS (earnings per share) of $0.18.

See more trading valuation data for Sino Biological
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$671M$1B0.9%0.9%-9.5%-4.8%$0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Sino Biological Valuation Multiples

Sino Biological trades at 6.5x EV/Revenue multiple, and 16.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Sino Biological

EV / Revenue (LTM)


Sino Biological Financial Valuation Multiples

As of June 2, 2026, Sino Biological has market cap of $1B and EV of $671M.

Sino Biological has a P/E ratio of 52.4x.

Last FY202320242025202620272028
EV/Revenue6.5x7.0x7.4x6.5x
EV/EBITDA16.6x12.6x19.2x16.6x
EV/EBIT43.5x27.7x83.0x43.5x
EV/Gross Profit8.9x8.6x10.1x8.9x
P/E52.4x29.8x63.5x52.4x
EV/FCF100.6x(6.3x)103.7x100.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Sino Biological Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Sino Biological Margins & Growth Rates

In the most recent fiscal year, Sino Biological reported gross margin of 73%, EBITDA margin of 39%, and net margin of 21%.

See estimated margins and future growth rates for Sino Biological

Sino Biological Margins

Last FY20242025202720282029
Gross Margin73%73%73%
EBITDA Margin39%39%39%
EBIT Margin15%9%15%
Net Margin21%20%21%
FCF Margin6%7%6%

Sino Biological Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(5%)14%
Gross Profit Growth(15%)14%
EBITDA Growth(35%)16%
EBIT Growth(67%)91%
Net Profit Growth(53%)21%
FCF Growth(106%)3%

Data powered by FactSet, Inc. and Morningstar, Inc.

Sino Biological Operational KPIs

Access forward-looking KPIs for Sino Biological
Last FY202320242025202620272028
S&M Expenses to Revenue5%7%7%5%
G&A Expenses to Revenue3%3%3%3%
R&D Expenses to Revenue12%14%15%12%
Opex to Revenue58%57%64%58%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Sino Biological Competitors

Sino Biological competitors include Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical, Oxford BioMedica, ACROBiosystems, Gubra, Sirio Pharma Co, Bora Pharmaceuticals and Akums Drugs and Pharma.

Most Sino Biological public comparables operate across Contract Research & Manufacturing, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Shanghai Medicilon6.5x6.0x(116.9x)-
Porton Pharma Solutions2.4x2.3x12.0x11.6x
Evotec1.1x1.1x20.9x32.2x
Aurisco Pharmaceutical4.8x4.6x12.1x11.3x
Oxford BioMedica4.8x4.2x336.1x72.8x
ACROBiosystems6.5x5.9x22.8x21.1x
Gubra1.8x2.7x2.2x3.8x
Sirio Pharma Co1.6x1.6x12.6x10.8x

This data is available for Pro users. Sign up to see all Sino Biological competitors and their valuation data.

Start Free Trial

Sino Biological VC Funding History

Before going public, Sino Biological raised $45M in total equity funding, across 2 rounds.


Sino Biological Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
May-18Undisclosed stageQiming Venture Partners$16M-Sino Biological is a life sciences company focused on recombinant protein manufacturing and reagent development. Founded in 2007, the company operates as a supplier of high-end biological reagents and technical services for life science research. Qiming Venture Partners led Sino Biological's initial funding rounds, first investing in a Series A financing in July 2017 that raised $30.7 million, followed by an additional investment of approximately $15.4 million in May 2018. The company grew significantly over subsequent years, eventually listing on Shenzhen's ChiNext Market on August 16, 2021, with an opening market capitalization of CNY 40.79 billion (approximately $6.3 billion USD at 2021 exchange rates). The IPO represented the company's evolution from an early-stage startup to a recognized leader in the recombinant protein industry with demonstrated revenue and profit growth.
Jul-17Series AQiming Venture Partners$30M-Sino Biological, a Chinese company specializing in recombinant proteins and antibodies for life sciences research, raised RMB 200 million (US$29 million) in a Series A round on July 6-7, 2017, led by Qiming Venture Partners. This was the company's first institutional financing round, with Qiming becoming its largest shareholder prior to its later IPO. The funding supported Sino Biological's growth in the antibody and drug development sector, positioning it as a provider of reagents and technical services. Post-2017, the company expanded significantly, achieving leadership in the recombinant protein industry with substantial revenue and profit growth by 2021. In August 2021, Sino Biological listed on Shenzhen's ChiNext Market (SZSE: 301047) at an issue price of CNY 292.92 per share, opening at CNY 599.9 for a market cap of CNY 40.79 billion. Qiming highlighted the company's transformation from startup to industry leader during this period.

Acquisitions by Sino Biological

Sino Biological has acquired 1 company to date.

Last acquisition by Sino Biological was on April 26th 2024. Sino Biological acquired SignalChem for $48M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Sino Biological

SignalChem
Description
SignalChem is a biotechnology company producing recombinant proteins for cell signaling research and drug discovery. Based in Richmond, British Columbia, Canada, the firm manufactures highly purified human proteins subjected to stringent quality controls, serving academic and biotech customers in kinase, phosphatase, and ubiquitin-related studies.
HQ CountryCanada
HQ City
-
Deal Date26 Apr 2024
Valuation$48M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sino Biological acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Sino Biological

Sino Biological has invested in 1 company to date.

Latest investment by Sino Biological was on February 2nd 2023. Sino Biological invested in PhaBuilder in their $53M Series A round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Sino Biological

PhaBuilder
PhaBuilder
Description
PhaBuilder is a synthetic biology firm engineering halophilic microbes for industrial applications through next-generation biotechnology. It produces biodegradable PHA polymers, ectoine as a pharmaceutical intermediate, and cadaverine for Nylon 56 precursors. Based in Beijing at the China-Germany Industrial Park, PhaBuilder develops products in its synthetic biology facility and constructs a PHA production plant in Yichang, Hubei Province. The company expands with additional large-scale bases across China.
PhaBuilder is a synthetic biology firm engineering halophilic microbes for industrial applications through next-generation biotechnology. It produces biodegradable PHA polymers, ectoine as a pharmaceutical intermediate, and cadaverine for Nylon 56 precursors. Based in Beijing at the China-Germany Industrial Park, PhaBuilder develops products in its synthetic biology facility and constructs a PHA production plant in Yichang, Hubei Province. The company expands with additional large-scale bases across China.
HQ CountryChinaChina
HQ City
Beijing
Beijing
Deal Date2 Feb 20234 Nov 2022
RoundSeries ASeries A
Raised$53M$13M
InvestorsAgricultural Fund of China; Chengtong Mixed Reform; FTZ Fund; Fuhua Capital; HSG; Kunlun Trust; Lingang Science and Technology Innovation; Sino Biological; Zhonghai InvestmentSino Biological
Valuation$287Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Sino Biological investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Sino Biological

When was Sino Biological founded?Sino Biological was founded in 2016.
Where is Sino Biological headquartered?Sino Biological is headquartered in China.
Is Sino Biological publicly listed?Yes, Sino Biological is a public company listed on Shenzhen Stock Exchange.
What is the stock symbol of Sino Biological?Sino Biological trades under 301047 ticker.
When did Sino Biological go public?Sino Biological went public in 2021.
Who are competitors of Sino Biological?Sino Biological main competitors include Shanghai Medicilon, Porton Pharma Solutions, Evotec, Aurisco Pharmaceutical, Oxford BioMedica, ACROBiosystems, Gubra, Sirio Pharma Co, Bora Pharmaceuticals, Akums Drugs and Pharma.
What is the current market cap of Sino Biological?Sino Biological's current market cap is $1B.
What is the current revenue of Sino Biological?Sino Biological's last fiscal year revenue is $103M.
What is the current EV/Revenue multiple of Sino Biological?Current revenue multiple of Sino Biological is 6.5x.
Is Sino Biological profitable?No, Sino Biological is not profitable.
How many companies Sino Biological has acquired to date?As of June 2026, Sino Biological has acquired 1 company.
What was the largest acquisition by Sino Biological?$48M acquisition of SignalChem on 26th April 2024 was the largest M&A Sino Biological has done to date.
What companies Sino Biological acquired?Sino Biological acquired SignalChem.
In how many companies Sino Biological has invested to date?As of June 2026, Sino Biological has invested in 1 company.
What was the last Sino Biological investment?On 2nd February 2023 Sino Biological invested in PhaBuilder, participating in a $53M Series A round at $287M valuation, alongside Agricultural Fund of China, Chengtong Mixed Reform, FTZ Fund, Fuhua Capital, HSG, Kunlun Trust, Lingang Science and Technology Innovation, and Zhonghai Investment.
In what companies Sino Biological invested in?Sino Biological invested in PhaBuilder.

See public comps similar to Sino Biological

Lists including Sino Biological

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial